NanoVibronix Inc (NAOV.OQ)
NAOV.OQ on NASDAQ Stock Exchange Capital Market
4.69USD
19 Apr 2018
4.69USD
19 Apr 2018
Change (% chg)
$0.08 (+1.74%)
$0.08 (+1.74%)
Prev Close
$4.61
$4.61
Open
$4.60
$4.60
Day's High
$4.69
$4.69
Day's Low
$4.40
$4.40
Volume
1,201
1,201
Avg. Vol
3,289
3,289
52-wk High
$4.99
$4.99
52-wk Low
$3.68
$3.68
Consensus Recommendations
Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
---|---|---|---|
Analyst Recommendations and Revisions
No analyst recommendations and revisions data available.
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
# of Estimates | Mean | High | Low | 1 Year Ago |
---|
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
---|---|---|---|---|
SALES (in millions) | ||||
Quarter Ending Sep-17 | 0.06 | 0.06 | 0.00 | 8.33 |
Quarter Ending Dec-16 | 0.08 | 0.05 | 0.03 | 34.67 |
Earnings (per share) | ||||
Quarter Ending Dec-16 | -0.11 | -0.25 | 0.14 | -127.27 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
---|
Estimates Revisions Summary
Last Week | Last 4 Weeks | |||
---|---|---|---|---|
Number Of Revisions: | Up | Down | Up | Down |
Revenue | ||||
Earnings |
- BRIEF-Nanovibronix Signs Instrumed Surgical As Exclusive Distributor For UroShield Products In Canada
- BRIEF-Nanovibronix Inc - Signed Morulaa Healthtech As Its Regulatory And Marketing Partner In India
- BRIEF-NanoVibronix Names IMS Ultrasound (UK) Ltd As Its Exclusive UK Distributor For Uroshield
- BRIEF-Nanovibronix Announces Exclusive U.K. Distributor For Painshield
- BRIEF-Nanovibronix Expects To Complete Trial For Use Of Painshield In Patients With Trigeminal Neuralgia In Q1 Of 2018